Cargando…
Case Report: Severe rebound after withdrawal of fingolimod in a patient with neuromyelitis optica spectrum disorder
PURPOSE: Fingolimod, an oral treatment for relapsing-remitting multiple sclerosis (RRMS), has been associated with a significant rebound in disease activity after therapy cessation. We described a patient with neuromyelitis optica spectrum disorder (NMOSD) who was previously diagnosed with RRMS and...
Autores principales: | Lin, Wei, Chou, Chung-Hsing, Yang, Fu-Chi, Tsai, Chia-Kuang, Lin, Yu-Kai, Sung, Yueh-Feng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140362/ https://www.ncbi.nlm.nih.gov/pubmed/37122715 http://dx.doi.org/10.3389/fimmu.2023.1115120 |
Ejemplares similares
-
Dramatic rebounds of MS during pregnancy following fingolimod withdrawal
Publicado: (2018) -
Dramatic rebounds of MS during pregnancy following fingolimod withdrawal
por: Novi, Giovanni, et al.
Publicado: (2017) -
The causal relationship between neuromyelitis optica spectrum disorder and other autoimmune diseases
por: Wang, Xiaofei, et al.
Publicado: (2022) -
Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
por: Ramanathan, Ramnath Santosh, et al.
Publicado: (2014) -
Complement biomarkers reflect the pathological status of neuromyelitis optica spectrum disorders
por: Miyamoto, Katsuichi, et al.
Publicado: (2023)